Exclusion of Disperse Orange 3 is possible from the textile dye mix present in the Swedish baseline patch test series. A study by the Swedish Contact Dermatitis Research Group.

allergic contact dermatitis contact allergy delayed hypersensitivity disperse dyes patch testing textile dermatitis

Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
Jan 2023
Historique:
revised: 12 09 2022
received: 04 07 2022
accepted: 13 09 2022
pubmed: 17 9 2022
medline: 21 12 2022
entrez: 16 9 2022
Statut: ppublish

Résumé

The textile dye mix (TDM) 6.6% in petrolatum contains Disperse Blue (DB) 35, Disperse Yellow 3, Disperse Orange (DO) 1 and 3, Disperse Red 1 and 17, and DB 106 and 124. The most frequent allergen in TDM-positive patients is DO 3. Around 85% of para-phenylenediamine (PPD)-allergic dermatitis patients have been positive to DO 3. There has been a discussion to exclude DO 3 from TDM 6.6% because of strong simultaneous reactions to TDM and PPD. To study if DO 3 can be excluded from TDM 6.6%. Patch tests were performed on 1481 dermatitis patients with TDM 6.6%, TDM 7.0% (without DO 3 but the other disperse dyes at 1.0% each), DO 3 1.0%, and PPD 1.0% pet. Contact allergy to TDM 6.6% was 3.6% and to TDM 7.0% was 3.0%. All 26 DO 3-positive patients were positive to PPD. The 44 patients positive to TDM 7.0% plus the 13 positive to PPD and TDM 6.6% but negative to TDM 7.0% were 57, outnumbering the 53 positive to TDM 6.6%. TDM 7.0% can replace TDM 6.6% in the Swedish baseline series, since TDM 7.0% together with PPD 1.0% will detect patients with textile dye allergy.

Sections du résumé

BACKGROUND BACKGROUND
The textile dye mix (TDM) 6.6% in petrolatum contains Disperse Blue (DB) 35, Disperse Yellow 3, Disperse Orange (DO) 1 and 3, Disperse Red 1 and 17, and DB 106 and 124. The most frequent allergen in TDM-positive patients is DO 3. Around 85% of para-phenylenediamine (PPD)-allergic dermatitis patients have been positive to DO 3. There has been a discussion to exclude DO 3 from TDM 6.6% because of strong simultaneous reactions to TDM and PPD.
OBJECTIVES OBJECTIVE
To study if DO 3 can be excluded from TDM 6.6%.
METHODS METHODS
Patch tests were performed on 1481 dermatitis patients with TDM 6.6%, TDM 7.0% (without DO 3 but the other disperse dyes at 1.0% each), DO 3 1.0%, and PPD 1.0% pet.
RESULTS RESULTS
Contact allergy to TDM 6.6% was 3.6% and to TDM 7.0% was 3.0%. All 26 DO 3-positive patients were positive to PPD. The 44 patients positive to TDM 7.0% plus the 13 positive to PPD and TDM 6.6% but negative to TDM 7.0% were 57, outnumbering the 53 positive to TDM 6.6%.
CONCLUSION CONCLUSIONS
TDM 7.0% can replace TDM 6.6% in the Swedish baseline series, since TDM 7.0% together with PPD 1.0% will detect patients with textile dye allergy.

Identifiants

pubmed: 36112512
doi: 10.1111/cod.14223
pmc: PMC10091765
doi:

Substances chimiques

Disperse Orange 3 B7J3O076OT
Disperse Orange 1 1592R4P97H
Coloring Agents 0
disperse blue 35 12222-75-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-59

Subventions

Organisme : HudFonden
Organisme : Finsen Foundation
Organisme : Edvard Welander Foundation

Informations de copyright

© 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.

Références

Acta Derm Venereol. 2015 Apr;95(4):427-31
pubmed: 25166030
PLoS One. 2014 Jul 17;9(7):e101717
pubmed: 25032825
Acta Derm Venereol. 2011 Jun;91(4):422-7
pubmed: 21547346
Contact Dermatitis. 2020 Nov;83(5):387-390
pubmed: 32666533
Dermatitis. 2020 Jan/Feb;31(1):e5-e7
pubmed: 31905185
Contact Dermatitis. 2014 Oct;71(4):215-23
pubmed: 24815318
Br J Dermatol. 2006 Apr;154(4):665-70
pubmed: 16536809
Contact Dermatitis. 2004 Aug;51(2):96-7
pubmed: 15373858
Contact Dermatitis. 2008 Mar;58(3):182-3
pubmed: 18279168
Contact Dermatitis. 1997 Feb;36(2):91-6
pubmed: 9062744
Contact Dermatitis. 2023 Jan;88(1):54-59
pubmed: 36112512
Contact Dermatitis. 2022 Oct;87(4):315-324
pubmed: 35611449
Contact Dermatitis. 2005 Sep;53(3):185
pubmed: 16128773
Contact Dermatitis. 2015 Oct;73(4):195-221
pubmed: 26179009
Contact Dermatitis. 2003 May;48(5):248-50
pubmed: 12868964
Dermatitis. 2015 Jul-Aug;26(4):170-6
pubmed: 26172486
Toxicol Lett. 2006 Mar 15;162(1):49-54
pubmed: 16361071
Contact Dermatitis. 2015 Jul;73(1):15-20
pubmed: 25925831
Contact Dermatitis. 1998 Aug;39(2):79-81
pubmed: 9746187
Clin Dermatol. 2011 May-Jun;29(3):316-24
pubmed: 21496741
Environ Pollut. 2021 Oct 15;287:117299
pubmed: 34023658
Contact Dermatitis. 2019 Jul;81(1):1-8
pubmed: 30684277
Contact Dermatitis. 2018 May;78(5):335-340
pubmed: 29392743
Contact Dermatitis. 2007 May;56(5):281-5
pubmed: 17441852

Auteurs

Marléne Isaksson (M)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Annarita Antelmi (A)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Jakob Dahlin (J)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Joanna Stenton (J)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Cecilia Svedman (C)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Erik Zimerson (E)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Bo Glas (B)

Department of Public Health and Clinical Medicine, Dermatology and Venereology, Umeå University, Umeå, Sweden.

Lina Hagvall (L)

Department of Dermatology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Maria Lagrelius (M)

Occupational and Environmental Dermatology, CAMM, Stockholm County Council and Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.

Anna Löwnertz (A)

Division of Dermatology and Venereology, Ryhov County Hospital, Jönköping, Sweden.

Laura Malinauskiene (L)

Faculty of Medicine, Institute of Clinical Medicine, Clinic of Chest Diseases, Immunology and Allergology, Vilnius University, Vilnius, Lithuania.

Mihaly Matura (M)

Department of Dermatology, Skaraborgs Hospital, Skövde, Sweden.

Magnus Bruze (M)

Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmö, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH